OBJECTIVE To elucidate the relationship between type-2 diabetes mellitus (DM) and overactive bladder symptoms in men with lower urinary tract symptoms (LUTS), after adjusting for the impact of age and prostate volume. MATERIALS AND METHODS Data were obtained from a prospectively maintained database of 905 first-visit patients with LUTS and benign prostatic hyperplasia. After excluding those w...

OBJECTIVES We evaluated the types of patient factors that influence the efficacy and safety of solifenacin add-on therapy to tamsulosin in men with overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH). METHODS A total of 130 BPH patients with persistent OAB symptoms despite undergoing alpha1-adrenagic antagonist monotherapy were enrolled in this study. Their OAB symptom...

Background: We aimed to assess the efficacy of Intraprostatic Onabotulinumtoxin-A (BTA) on the International Prostate Symptom Score (IPSS) and other objective measures of patients with Benign Prostatic Hyperplasia (BPH). Methods: Fifteen patients were included in this study. The drug (BTA; 150 IU) was reconstituted in 20 mL of 0.9% saline before administration to the patients. After providing ...

PURPOSE In Korea, there was no specific guidelines for the management of benign prostatic hyperplasia (BPH). We reviewed the practice patterns of Korean urologists in the management of BPH and aimed to describe the need to develop specific guidelines. MATERIALS AND METHODS A probability sample was taken from the Korean Urological Association Registry of Physicians, and a structured questionna...

Recent studies have focused on the relationship between nocturia and serum testosterone because testosterone is thought to be an important factor of prostate growth. However, it remains unclear whether altered serum concentrations of testosterone is associated with an increased risk of nocturia because patients who were taking diuretics or who had a large prostate, which may precipitate nocturi...

CONTEXT Interest in having alternatives in the treatment of benign prostate hyperplasia. OBJECTIVES To assess the efficacy and safety of the Urolift® system for treating the symptoms of benign prostate hyperplasia. ACQUISITION OF EVIDENCE Systematic review of the literature through searches on PubMed, Cochrane Library, CRD, Clinical Trials and EuroScan, collecting indicators of efficacy and...

When physician carries out the clinical survey of a patient with benign prostatic hyperplasia (BPH) symptom to reach the initial evaluation/diagnosis of BPH symptom, the existing initial evaluation method of BPH based on the international prostate symptom score (I-PSS) usually use the objective evaluation/diagnosis method with crisp values without considering fuzzy information. However, this no...

PURPOSE Posterior rhabdosphincter reconstruction following radical prostatectomy was designed to improve early urinary continence. We executed a randomized clinical trial to test this conjecture in men undergoing robotic radical prostatectomy. MATERIALS AND METHODS We conducted a phase II randomized clinical trial intended to detect a 25% difference in 3-month continence outcomes defined by a...

Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-spe...

METHODS: This is a retrospective observational cohort study: one cohort includes patients who underwent endoscopic surgery, and the other patients undergoing laser therapy (vaporization). A total of 106 patients were included, divided into two cohorts. Two questionnaires were prepared for those who fulfilled inclusion criteria, the International Prostate Symptom Score (IPSS), two months before ...